Inactive Instrument

Forward Pharma A/S Stock price

Equities

FWPAY

US34986J3032

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 14-12-31
Comptroller/Controller/Auditor 67 14-07-31
Members of the board TitleAgeSince
Director/Board Member 65 16-05-05
Founder 55 05-06-30
Director/Board Member 65 06-05-31
More insiders
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
More about the company
  1. Stock
  2. Equities
  3. Stock Forward Pharma A/S - OTC Markets